| |
Study site
|
Drug regime
|
No of children
|
Prevalence of anaemia (%)
|
PE (95 % CI)
|
|---|
|
Clarke [24]
|
Bondo
|
SP + AQ (four-monthly)
|
2604
|
6.3
|
50 (41–53)
|
| | |
Placebo
|
2302
|
12.6
|
–
|
|
Barger [25]
|
Kollé
|
SP + AS
|
96
|
17.7
|
40 (9–61)
|
| | |
AQ + AS
|
100
|
16
|
46 (17–65)
|
| | |
Control
|
98
|
29.6
|
–
|
|
Nankabirwa [27]
|
Tororo
|
DP (monthly)
|
717a
|
12
|
40 (29–49)
|
| | |
DP (three and five monthly)
|
716a
|
17
|
14 (2–23)
|
| | |
Placebo
|
736a
|
20
|
–
|
-
PE protective effect, No number, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine, % percentage
-
aTotal tests
